Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug zigakibart aims to slow kidney disease in IgA nephropathy patients

NCT ID NCT07146906

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This study tests a drug called zigakibart in 32 adults with IgA nephropathy, a kidney disease. The goal is to see if it can reduce signs of kidney damage and slow disease progression. Participants must have a recent kidney biopsy and persistent protein in their urine despite standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN A NEPHROPATHY (IGAN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNOGLOBULIN A NEPHROPATHY (IGAN)

Contacts and locations

Locations

  • American Clinical Trials

    RECRUITING

    Acworth, Georgia, 30101, United States

  • Colorado Kidney Care Nephrology

    RECRUITING

    Denver, Colorado, 80230, United States

  • Inter Med Consultants

    RECRUITING

    Edina, Minnesota, 55435, United States

  • Novartis Investigative Site

    RECRUITING

    Serra, Espírito Santo, 29160-750, Brazil

  • Novartis Investigative Site

    RECRUITING

    Recife, Pernambuco, 50740-900, Brazil

  • Novartis Investigative Site

    RECRUITING

    Natal, Rio Grande do Norte, 59012 300, Brazil

  • Novartis Investigative Site

    RECRUITING

    Botucatu, São Paulo, 3880-1001, Brazil

  • Novartis Investigative Site

    RECRUITING

    Beijing, 100034, China

  • Novartis Investigative Site

    RECRUITING

    Shanghai, 200025, China

  • Novartis Investigative Site

    RECRUITING

    Prague, 128 08, Czechia

  • Novartis Investigative Site

    RECRUITING

    Munich, Bavaria, 81377, Germany

  • Novartis Investigative Site

    RECRUITING

    Hanover, 30625, Germany

  • Novartis Investigative Site

    RECRUITING

    Mainz, 55131, Germany

  • Novartis Investigative Site

    RECRUITING

    Ranica, BG, 24020, Italy

  • Novartis Investigative Site

    RECRUITING

    Brescia, BS, 25123, Italy

  • Novartis Investigative Site

    RECRUITING

    Pavia, PV, 27100, Italy

  • Novartis Investigative Site

    RECRUITING

    Kawasaki, Kanagawa, 213-8587, Japan

  • Novartis Investigative Site

    RECRUITING

    Miyazaki, 889-1692, Japan

  • Novartis Investigative Site

    RECRUITING

    Lodz, 92-213, Poland

  • Novartis Investigative Site

    RECRUITING

    Opole, 45-401, Poland

  • Novartis Investigative Site

    RECRUITING

    Seoul, Seoul, 03080, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    RECRUITING

    Pamplona, Navarre, 31008, Spain

  • Novartis Investigative Site

    RECRUITING

    Valencia, Valencia, 46017, Spain

  • Novartis Investigative Site

    RECRUITING

    Barcelona, 08036, Spain

  • Novartis Investigative Site

    RECRUITING

    Seville, 41013, Spain

  • Novartis Investigative Site

    RECRUITING

    Kaohsiung City, 833, Taiwan

  • Novartis Investigative Site

    RECRUITING

    Taipei, 10002, Taiwan

  • Univ Of Iowa Hospitals And Clinics

    RECRUITING

    Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.